-
公开(公告)号：US20210338670A1
公开(公告)日：2021-11-04
申请号：US17246291
申请日：2021-04-30
发明人： Giuseppe Carlucci , Thomas Reiner
IPC分类号： A61K31/506 , G01N33/574
摘要： Disclosed are compounds having the following structure: CDK-L-(X)n, where CDK is a CDK4/6 inhibitor group, L is a linking group, X is a radiolabel or hydrogen, n is 1, 2, 3, 4, or 5, and when there are a plurality of X groups, at least one X is a radiolabel. Also described are methods of making and using the compounds. The compounds may be used in PET imaging to quantify CDK4/6 expression in cancers and to treat cancer patients exhibiting tumors which express CDK4/6.
-
公开(公告)号：US20210315868A1
公开(公告)日：2021-10-14
申请号：US16640146
申请日：2018-08-24
发明人： Frederic GEISSMANN , Elvira MASS , Rocio VICARIO
IPC分类号： A61K31/437 , A61K45/06 , A61P25/28
摘要： The present technology relates to methods for treating, preventing, and/or ameliorating kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases, in a subject in need thereof. In particular aspects, the present technology relates to the use of BRAF, MEK, and/or CSF-IR inhibitors to treat, prevent, and/or ameliorate kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases.
-
公开(公告)号：US20210308285A1
公开(公告)日：2021-10-07
申请号：US17349723
申请日：2021-06-16
发明人： Mark Dunphy , Gabriela Chiosis
IPC分类号： A61K51/04 , A61P35/00 , A61K49/00 , A61B5/318 , A61B5/0275 , A61B5/08 , A61B5/00 , A61B6/03 , A61B6/00 , A61K31/52 , A61K49/18
摘要： The present invention provides new methods for inflammation and infection imaging and related medical applications thereof. In some embodiments, the present invention provides a method for the diagnosis of inflammation and/or infection. In some embodiments, the present invention provides a method for the treatment or prevention of inflammation and/or infection. In some embodiments, the present invention provides methods for monitoring the effect of inflammation and/or infection treatment, and/or methods for monitoring an inflammation and/or infection treatment regimen. In some embodiments, the present invention provides a method for selecting subjects for an inflammation and/or infection treatment. In some embodiments, the present invention provides a method for determining the dosage of a drug for the treatment of inflammation and/or infection.
-
公开(公告)号：US11136392B2
公开(公告)日：2021-10-05
申请号：US15849107
申请日：2017-12-20
IPC分类号： C07K16/28 , A61K39/395 , A61K35/17 , A61K48/00 , C07K14/705 , C07K14/725 , A61K47/68 , A61P35/00 , C07K16/30 , A61K39/00 , A61K38/00 , A61K35/12
摘要： The present application provides anti-PD-1 antigen-binding proteins or a fragment thereof, as well as nucleic acids encoding anti-PD-1 antigen-binding proteins or CAR T cells expressing such antigen-binding protein or fragment. Also provided are methods of regulating T cells or treating patients using such constructs or cells.
-
95.发明申请公开(公告)号：US20210301014A1
公开(公告)日：2021-09-30
申请号：US17229007
申请日：2021-04-13
发明人： Sarah CHEAL , Hong XU , Steven LARSON , Nai-Kong CHEUNG , Karl Dane WITTRUP , Alice TZENG
摘要： Described herein are multi-specific binding agents that bind A33 and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. Also provided herein are methods of using multi-specific binding agents or compositions thereof for the detection, prevention, and/or therapeutic treatment of diseases characterized by expression of the A33 glycoprotein antigen, in particular, colorectal cancer.
-
96.发明申请公开(公告)号：US20210295111A1
公开(公告)日：2021-09-23
申请号：US17134886
申请日：2020-12-28
摘要： The present disclosure discusses systems and methods to detect blur in digital images. The solution can be incorporated into the quality control systems of pathology and other slide scanners or can be a stand-alone solution. The solution can identify scanned images that include blur and cause the scanner to automatically rescan the blurry image. The solution can also identify regions of the scanned image that include blur. The solution can generate blur maps for each of the scanned images that identify regions of the scanned image that include blur.
-
公开(公告)号：US20210292075A1
公开(公告)日：2021-09-23
申请号：US17222527
申请日：2021-04-05
发明人： STEVEN WANG
IPC分类号： B65D81/32 , A61K8/67 , B65D75/58 , A61K8/02 , A45D44/00 , A61Q19/08 , B65D25/08 , B65D79/02 , B65D41/02
摘要： According to an exemplary embodiment of the present disclosure, a cosmetic arrangement can be provided, which can include a first structure that can enclose a cosmetic active ingredient(s), a second structure that can enclose a solvent solution, a third structure(s) that can separate the solvent solution from the cosmetic active ingredient(s), a medium that can be configured to absorb a mixture of the cosmetic active ingredient(s) and solvent solution, and an indicator structure that can be configured to indicate whether the cosmetic active ingredient(s) and the solvent solution have come in contact with one another. Upon an application of a particular amount of pressure on a portion(s) of the arrangement, the cosmetic active ingredient(s) and the solvent solution can be caused to come into direct contact with one another.
-
公开(公告)号：US11117964B2
公开(公告)日：2021-09-14
申请号：US16484451
申请日：2018-02-26
发明人： Katharine Hsu , Nai-Kong V. Cheung , Su Yan , Yiyang Xu , Jingyi Xiang , Cheng Liu
IPC分类号： C07K16/28 , A61K39/295 , A61P35/02 , G01N33/53 , C12N5/10 , C12N15/63 , C12N15/11 , A61K47/68 , A61K39/395 , A61K45/06 , C07K14/705
摘要： The disclosure provides antibody agents that bind to inhibitory human killer immunoglobulin-like receptors (KIRs). Particular antibody agents of the disclosure include antibody agents that bind to KIR3DL1 (also known as CD158e). Also provided are related nucleic acids, vectors, compositions and methods of using KIR-binding antibody agents of the present technology.
-
公开(公告)号：US11116757B2
公开(公告)日：2021-09-14
申请号：US16683076
申请日：2019-11-13
发明人： Jaeki Min , Daniel C. Scott , Deepak Bhasin , Brenda A. Schulman , Bhuvanesh Singh , Jared T. Hammill , R. Kiplin Guy
IPC分类号： A61K31/4545 , C07D401/12 , C07D211/58 , C07D401/06 , C07D409/14 , C07D405/12 , C07D417/06 , C07D471/04 , C07D405/06 , C07D401/04 , C07D417/04 , A61P31/12 , A61P15/16 , A61P31/04 , A61K31/17 , A61K31/437 , A61K31/451 , A61K31/4525 , A61K31/454 , A61K31/506
摘要： In one aspect, the invention relates to substituted 1-phenyl-3-(piperidin-4-yl)urea analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the DCN1-UBC12 interaction inhibitors of DCN1-mediated cullin-RING ligase activity, methods of making same, pharmaceutical compositions comprising same, methods of treating disorders using the disclosed compounds and compositions, methods of treating disorders associated with a DCN1-UBC12 interaction dysfunction, methods of treating disorders associated with a DCN1-mediated cullin-RING ligase activity dysfunction, methods of male contraception comprising the disclosed compounds and compositions, and kits comprising the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
-
公开(公告)号：US20210277454A1
公开(公告)日：2021-09-09
申请号：US17324093
申请日：2021-05-18
IPC分类号： C12Q1/6837 , C12N15/10 , G01N33/574
摘要： The present disclosure relates to an array-based assay for transposase-accessible chromatin and prognostic molecular markers of treatment-resistant/early recurrent cancer. The present disclosure also relates to predicting an outcome, such as duration of disease-free survival, in a cancer patient.
-
-
-
-
-
-
-
-
-
搜索结果
1283 条记录 (耗时 0.049 秒)
